Autotaxin and Breast Cancer: Towards Overcoming Treatment Barriers and Sequelae
After a decade of intense preclinical investigations, the first in-class autotaxin inhibitor, GLPG1690, has entered Phase III clinical trials for idiopathic pulmonary fibrosis. In the intervening time, a deeper understanding of the role of the autotaxin−lysophosphatidate (LPA)−li...
Main Authors: | Matthew G. K. Benesch, Xiaoyun Tang, David N. Brindley |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-02-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/12/2/374 |
Similar Items
-
Coming of Age for Autotaxin and Lysophosphatidate Signaling: Clinical Applications for Preventing, Detecting and Targeting Tumor-Promoting Inflammation
by: Matthew G.K. Benesch, et al.
Published: (2018-03-01) -
Autotaxin, lysophosphatidate and taxol resistance
by: Samadi, Nasser
Published: (2009) -
PDGFRα Enhanced Infection of Breast Cancer Cells with Human Cytomegalovirus but Infection of Fibroblasts Increased Prometastatic Inflammation Involving Lysophosphatidate Signaling
by: Zelei Yang, et al.
Published: (2021-09-01) -
Autotaxin-LPA-LPP3 Axis in Energy Metabolism and Metabolic Disease
by: Anu Jose, et al.
Published: (2021-09-01) -
LPA receptor 4 deficiency attenuates experimental atherosclerosis
by: Liping Yang, et al.
Published: (2019-05-01)